Duni’s Q2 net sales were SEK 1,936m with organic growth of 5.6% supported by price increases as volumes were slightly lower y/y. Despite this, the operating margin of 8.8% exceeded our estimated 7.5%, supported by better-than-expected effects from operational leverage and price increases. BioPak also continues to show a positive trend in normalising inventory levels, supporting cash flow. The report suggests potential positive single-digit earnings revisions for FY/23.

https://research.sebgroup.com/corporate/reports/121588

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.